aTyr Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-50.39	-45.34	-33.77	-16.22	-23.6	Upgrade
Depreciation & Amortization	2.74	1.7	1.3	1.27	1.37	Upgrade
Share-Based Compensation	2.6	2.15	1.61	1.47	1.78	Upgrade
Other Operating Activities	11.83	-0.4	-2.23	-1.81	0.44	Upgrade
Operating Cash Flow	-33.22	-41.89	-33.08	-15.3	-20.01	Upgrade
Capital Expenditures	-4.2	-1.46	-0.14	-0.18	-0.03	Upgrade
Change in Investments	-15.93	48.71	-91.42	7.08	4.95	Upgrade
Investing Cash Flow	-20.13	47.25	-91.57	6.9	4.93	Upgrade
Share Issuance / Repurchase	66.62	5.52	110.03	25.23	9.34	Upgrade
Debt Issued / Paid	-0.39	-0.07	0	-9.08	-8	Upgrade
Financing Cash Flow	66.23	5.45	110.03	16.14	1.34	Upgrade
Net Cash Flow	12.88	10.81	-14.62	7.74	-13.75	Upgrade
Free Cash Flow	-37.42	-43.35	-33.22	-15.49	-20.04	Upgrade
Free Cash Flow Margin	-10600.85%	-417.37%	-	-148.11%	-4749.05%	Upgrade
Free Cash Flow Per Share	-0.70	-1.52	-1.74	-1.69	-5.97	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).